If you have been reading about GW501516 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
The Gibson assembly method is a relatively straightforward DNA assembly method, requiring only a few additional reagents: the 5' T5 exonuclease, Phusion DNA polymerase, and Taq DNA ligase. The DNA fragments to be assembled are synthesised to have overlapping 5' and 3' ends in the order that they are to be assembled in. These reagents are mixed together with the DNA fragments to be assembled at 50 °C and the following reactions occur:
The use of RdRp plays a major role in RNA interference in eukaryotes, a process used to silence gene expression via small interfering RNAs (siRNAs) binding to mRNA rendering them inactive. Eukaryotic RdRp becomes active in the presence of dsRNA, and is less widely distributed than other RNAi components as it lost in some animals, though still found in C. elegans, P. tetraurelia, and plants. This presence of dsRNA triggers the activation of RdRp and RNAi processes by priming the initiation of RNA transcription through the introduction of siRNAs. In C. elegans, siRNAs are integrated into the RNA-induced silencing complex, RISC, which works alongside mRNAs targeted for interference to recruit more RdRps to synthesize more secondary siRNAs and repress gene expression. Spiegelman's Monster NS5B inhibitor RNA+Replicase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 2.7.7.48
100. Tirzepatide. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2026 Aug 15. Tirzepatide is usually undetectable in breastmilk with subcutaneous doses of up to 5 mg. Furthermore, absorption by the infant is unlikely because it is probably partially destroyed in the infant’s gastrointestinal tract and poorly absorbed orally. If a mother requires tirzepatide, it is not a reason to discontinue breastfeeding. Until more data become available, tirzepatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some experts recommend closely monitoring of infant growth and developmental milestones and the nutritional status of the lactating woman.[1]
Clear Lake Audiotorium is a six-track promo EP by De La Soul given out to A-list DJs in 1994, the catalog number is TB 1093 (Side A, "THIS SIDE" is TB 1093 A and Side B "OTHER SIDE" is TB 1093 B). It was composed of four tracks from the group's album Buhloone Mindstate and two non-album tracks—"Sh.Fe.Mc's" featuring A Tribe Called Quest, and "Stix & Stonz" featuring The Fearless Four, Grandmaster Caz, and Prince Whipper Whip. With only 500 copies pressed (vinyl and CD), Clear Lake Audiotorium remains one of the most sought-after De La Soul releases to date. Originally pressed on clear/light green vinyl and packaged in a clear plastic sleeve, the record has since been bootlegged on black vinyl. On March 7, 2025, exactly 31 years after its original release, the EP was released officially on streaming releases, alongside a limited physical re-release.
Sources: en.wikipedia.org
It is thought that high glucagon levels and lack of insulin production are the main triggers for the metabolic issues associated with Type I diabetes, in particular maintaining normal blood glucose levels, formation of ketone bodies, and formation of urea. One finding of note is that the glucagon response to hypoglycemia is completely absent in patients with Type I diabetes. Consistently high glucagon concentrations in the blood can lead to diabetic ketoacidosis, which is when ketones from lipid breakdown build up in the blood, which can lead to dangerously low blood glucose levels, low potassium levels, and in extreme cases cerebral edema. It has been proposed that the reason for the high levels of glucagon found in the plasma of patients with Type I diabetes is the absence of beta cells producing insulin and the reciprocal effect this has on delta cells and the secretion of somatostatin.
An ion-exchange membrane is a semi-permeable membrane that transports certain dissolved ions, while blocking other ions or neutral molecules. Ion-exchange membranes are therefore electrically conductive. They are often used in desalination and chemical recovery applications, moving ions from one solution to another with little passage of water. Important examples of ion-exchange membranes include the proton-exchange membranes, that transport H+ cations, and the anion exchange membranes used in certain alkaline fuel cells to transport OH− anions.
Biopharmaceuticals may be produced from microbial cells (e.g., recombinant E. coli or yeast cultures), mammalian cell lines (see Cell culture) and plant cell cultures (see Plant tissue culture) and moss plants in bioreactors of various configurations, including photo-bioreactors. Important issues of concern are cost of production (low-volume, high-purity products are desirable) and microbial contamination (by bacteria, viruses, mycoplasma). Alternative platforms of production which are being tested include whole plants (plant-made pharmaceuticals).
Sources: en.wikipedia.org
Christopher A. Lipinski is a medicinal chemist who is working at Pfizer, Inc. He is known for his "rule of five", an algorithm that predicts drug compounds that are likely to have oral activity. By the number of citations, he is the most cited author of some pharmacology journals: Journal of Pharmacological and Toxicological Methods, Advanced Drug Delivery Reviews, Drug Discovery Today: Technologies. Lipinski received his PhD from the University of California, Berkeley in 1968 in physical organic chemistry. The Advanced Drug Delivery Reviews article reporting his "rule of five" is one of the most cited publications in the journal's history. In 2006, he received an honorary law degree from the University of Dundee and he has won various awards, including being the Society for Biomolecular Sciences' winner of the 2006 SBS Achievement Award for Innovation in HTS.
BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California. It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the United Kingdom. In July 2021, BioLegend was acquired by PerkinElmer for $5.25 billion and now operates as Revvity. BioLegend manufactures products in the areas of neuroscience, cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies. Reagents are created for use in flow cytometry, proteogenomics, ELISA, immunoprecipitation, Western blotting, immunofluorescence microscopy, immunohistochemistry, and in vitro or in vivo functional assays.
SSEP can be used to locate lesions such as peripheral nerve or spinal cord. VEP and BAEP can supplement neuroimaging as part of workups to diagnose diseases such as multiple sclerosis. Short latency EPs such as SSEP, VEP, and BAEP can be used to indicate prognosis for traumatic and anoxic brain injury. Early after anoxic brain injury, no response indicates mortality accurately. In traumatic brain injury, abnormal responses indicates failure to recover from coma. In both types of injury, normal responses may indicate good outcome. Moreover, recovery in responses often indicates clinical recovery. Long and Allen were the first investigators to report the abnormal brainstem auditory evoked potentials (BAEPs) in an alcoholic woman who recovered from acquired central hypoventilation syndrome. These investigators hypothesized that their patient's brainstem was poisoned, but not destroyed, by her chronic alcoholism.
Activated carbon, in 50% w/w combination with celite, is used as stationary phase in low-pressure chromatographic separation of carbohydrates (mono-, di-, tri-saccharides) using ethanol solutions (5–50%) as mobile phase in analytical or preparative protocols. Activated carbon is useful for extracting the direct oral anticoagulants (DOACs) such as dabigatran, apixaban, rivaroxaban and edoxaban from blood plasma samples. For this purpose it has been made into "minitablets", each containing 5 mg activated carbon for treating 1ml samples of DOAC. Since this activated carbon has no effect on blood clotting factors, heparin or most other anticoagulants this allows a plasma sample to be analyzed for abnormalities otherwise affected by the DOACs. Carbon adsorption has numerous applications in removing pollutants from air or water streams both in the field and in industrial processes such as:
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.